Abaxis Inc (ABAX) 49.14 $ABAX
New Strong Sell Stocks for July 29th
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:03AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
CAJ: 28.18 (-0.09), OLED: 73.82 (+2.98), ABAX: 49.14 (-0.32), BJRI: 39.33 (+0.49), HMC: 27.29 (+0.17)
Shares of ABAX Up 19.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 14, 1:53PM CDT
SmarTrend identified an Uptrend for Abaxis (NASDAQ:ABAX) on March 30th, 2016 at $44.30. In approximately 4 months, Abaxis has returned 19.89% as of today's recent price of $53.11.
ABAX: 49.14 (-0.32)
Abaxis To Report First Quarter Fiscal Year 2017 Financial Results On Thursday, July 21, 2016
PR Newswire - Wed Jul 13, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the first quarter fiscal year 2017, ended June 30, 2016. The call will be at 4:15 p.m. ET on Thursday, July 21, 2016. The Company will report financial results for the first quarter fiscal year 2017 after the market closes on Thursday, July 21, 2016.
ABAX: 49.14 (-0.32)
Point of Care (PoC) Lipid Test Market Size & Forecast By Instruments (Brand Market Sizing: Roche Reflotron, Roche Cobas b 101, Abaxis Piccolo, Alere Cholestech LDX, Alere Afinion, Samsung LABGEO, PTS CardioChek), By Application (Hyperlipidemia, Hypertrigl
PR Newswire - Wed Jun 22, 4:33PM CDT
Global Point of care (PoC) Lipid Test market is expected to reach USD 280.02 million by 2022 according to a new report by Grand View Research Inc. Growing geriatric population base, increasing global prevalence of cardiovascular diseases, and rising healthcare awareness due to patient education are the driving forces for the PoC Lipid Test industry growth during the forecast period.
ABAX: 49.14 (-0.32)
Abaxis Global Diagnostics and AAHA Develop Preventive Care Testing Initiative
PR Newswire - Mon Jun 06, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today announced a partnership with the American Animal Hospital Association (AAHA) to develop a wellness testing initiative that is focused on improving compliance for blood diagnostic testing.
ABAX: 49.14 (-0.32)
Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:01AM CDT
On Jun 3, 2016, we issued an updated research report on Abaxis, Inc. (ABAX). The stock currently carries a Zacks Rank #4 (Sell).
ICUI: 117.07 (+0.31), ABAX: 49.14 (-0.32), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09)
Abaxis, Inc. to Present at the Jefferies 2016 Global Healthcare Conference
PR Newswire - Wed Jun 01, 7:02AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, announced today that Ross Taylor, chief financial officer, will present at the Jefferies 2016 Global Healthcare Conference on Tuesday, June 7, 2016 at 10:30 a.m. ET. The conference will be held at the Grand Hyatt in New York City.
ABAX: 49.14 (-0.32)
New Strong Sell Stocks for May 31st
Swarup Gupta - Zacks Investment Research - Tue May 31, 8:27AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
ABAX: 49.14 (-0.32), ASB: 18.38 (-0.22), AHT: 5.90 (-0.06), CIT: 34.14 (-0.42), MATX: 37.67 (+0.30)
Abaxis, Inc. to Present at the Stifel 2016 Dental & Veterinary Conference
PR Newswire - Wed May 25, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, announced today that Ross Taylor, chief financial officer, will present at the Stifel 2016 Dental & Veterinary Conference on Wednesday, June 1, 2016 at 8:00 a.m. ET. The conference will be held at The Peninsula Hotel in New York City.
ABAX: 49.14 (-0.32)
Abaxis (ABAX) Posts Solid Q4 amid International Headwind
Zacks Equity Research - Zacks Investment Research - Wed May 25, 5:28AM CDT
On May 18, 2016, we issued an updated research report on Abaxis, Inc. (ABAX).
ICUI: 117.07 (+0.31), ABAX: 49.14 (-0.32), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09)
New Strong Sell Stocks for May 12th
Zacks Equity Research - Zacks Investment Research - Thu May 12, 6:59AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
ABC: 85.54 (+0.35), ABAX: 49.14 (-0.32), AMID: 10.97 (-1.05), ABBV: 66.94 (+0.71), FCCY: 12.40 (-0.10)
Global Biochip Market Worth USD 18.4 Billion by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: 3Qbd, Abaxis Inc, Emulate Inc - Research and Markets
BusinessWire - Thu May 05, 4:36AM CDT
Research and Markets has announced the addition of the "Global Biochip Markets: Microarrays and Lab-on-a-Chip" report to their offering.
ABAX: 49.14 (-0.32)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 24.43 (+0.15), CAPR: 3.58 (-0.12), CSII: 19.50 (-0.11), ABAX: 49.14 (-0.32)
Abaxis tops Street 4Q forecasts
Automated Insights - Thu Apr 28, 4:49PM CDT
UNION CITY, Calif. (AP) _ Abaxis Inc. (ABAX) on Thursday reported fiscal fourth-quarter earnings of $8.9 million.
ABAX: 49.14 (-0.32)
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2016 and Declares a 9% Increase in Quarterly Cash Dividend
PR Newswire - Thu Apr 28, 3:01PM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the fourth quarter and fiscal year ended March 31, 2016.
ABAX: 49.14 (-0.32)
Abaxis To Report Fourth Quarter And Fiscal Year 2016 Financial Results On Thursday, April 28, 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2016, ended March 31, 2016. The call will be at 4:15 p.m. ET on Thursday, April 28, 2016. The Company will report financial results for the fourth quarter and fiscal year 2016 after the market closes on Thursday, April 28, 2016.
ABAX: 49.14 (-0.32)
Global Veterinary Diagnostics Market Report 2014-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abaxis, HESKA, IDEXX Labs - Research and Markets
BusinessWire - Tue Apr 12, 7:26AM CDT
Research and Markets has announced the addition of the "Veterinary Diagnostics Global Market Analysis - Forecast (2014-2022)" report to their offering.
ABAX: 49.14 (-0.32)
Global Blood Gas and Electrolyte Analyzer Industry
PR Newswire - Mon Apr 04, 6:43PM CDT
This report analyzes the worldwide markets for Blood Gas and Electrolyte Analyzers in Units and US$ Thousand by the following Product Segments: Blood Gas Analyzers (Benchtop Analyzers, & Point-of-Care Analyzers), and Electrolyte Analyzers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -
ABAX: 49.14 (-0.32)
Abaxis Down 21.1% Since SmarTrend Downtrend Call (ABAX)
Comtex SmarTrend(R) - Mon Feb 08, 4:31PM CST
SmarTrend identified a Downtrend for Abaxis (NASDAQ:ABAX) on January 11th, 2016 at $51.04. In approximately 4 weeks, Abaxis has returned 21.14% as of today's recent price of $40.25.
ABAX: 49.14 (-0.32)
New Strong Sell Stocks for July 29th
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:03AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
CAJ: 28.18 (-0.09), OLED: 73.82 (+2.98), ABAX: 49.14 (-0.32), BJRI: 39.33 (+0.49), HMC: 27.29 (+0.17)
Shares of ABAX Up 19.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 14, 1:53PM CDT
SmarTrend identified an Uptrend for Abaxis (NASDAQ:ABAX) on March 30th, 2016 at $44.30. In approximately 4 months, Abaxis has returned 19.89% as of today's recent price of $53.11.
ABAX: 49.14 (-0.32)
Abaxis To Report First Quarter Fiscal Year 2017 Financial Results On Thursday, July 21, 2016
PR Newswire - Wed Jul 13, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the first quarter fiscal year 2017, ended June 30, 2016. The call will be at 4:15 p.m. ET on Thursday, July 21, 2016. The Company will report financial results for the first quarter fiscal year 2017 after the market closes on Thursday, July 21, 2016.
ABAX: 49.14 (-0.32)
Point of Care (PoC) Lipid Test Market Size & Forecast By Instruments (Brand Market Sizing: Roche Reflotron, Roche Cobas b 101, Abaxis Piccolo, Alere Cholestech LDX, Alere Afinion, Samsung LABGEO, PTS CardioChek), By Application (Hyperlipidemia, Hypertrigl
PR Newswire - Wed Jun 22, 4:33PM CDT
Global Point of care (PoC) Lipid Test market is expected to reach USD 280.02 million by 2022 according to a new report by Grand View Research Inc. Growing geriatric population base, increasing global prevalence of cardiovascular diseases, and rising healthcare awareness due to patient education are the driving forces for the PoC Lipid Test industry growth during the forecast period.
ABAX: 49.14 (-0.32)
Abaxis Global Diagnostics and AAHA Develop Preventive Care Testing Initiative
PR Newswire - Mon Jun 06, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today announced a partnership with the American Animal Hospital Association (AAHA) to develop a wellness testing initiative that is focused on improving compliance for blood diagnostic testing.
ABAX: 49.14 (-0.32)
Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:01AM CDT
On Jun 3, 2016, we issued an updated research report on Abaxis, Inc. (ABAX). The stock currently carries a Zacks Rank #4 (Sell).
ICUI: 117.07 (+0.31), ABAX: 49.14 (-0.32), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09)
Abaxis, Inc. to Present at the Jefferies 2016 Global Healthcare Conference
PR Newswire - Wed Jun 01, 7:02AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, announced today that Ross Taylor, chief financial officer, will present at the Jefferies 2016 Global Healthcare Conference on Tuesday, June 7, 2016 at 10:30 a.m. ET. The conference will be held at the Grand Hyatt in New York City.
ABAX: 49.14 (-0.32)
New Strong Sell Stocks for May 31st
Swarup Gupta - Zacks Investment Research - Tue May 31, 8:27AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
ABAX: 49.14 (-0.32), ASB: 18.38 (-0.22), AHT: 5.90 (-0.06), CIT: 34.14 (-0.42), MATX: 37.67 (+0.30)
Abaxis, Inc. to Present at the Stifel 2016 Dental & Veterinary Conference
PR Newswire - Wed May 25, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, announced today that Ross Taylor, chief financial officer, will present at the Stifel 2016 Dental & Veterinary Conference on Wednesday, June 1, 2016 at 8:00 a.m. ET. The conference will be held at The Peninsula Hotel in New York City.
ABAX: 49.14 (-0.32)
Abaxis (ABAX) Posts Solid Q4 amid International Headwind
Zacks Equity Research - Zacks Investment Research - Wed May 25, 5:28AM CDT
On May 18, 2016, we issued an updated research report on Abaxis, Inc. (ABAX).
ICUI: 117.07 (+0.31), ABAX: 49.14 (-0.32), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09)
New Strong Sell Stocks for May 12th
Zacks Equity Research - Zacks Investment Research - Thu May 12, 6:59AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
ABC: 85.54 (+0.35), ABAX: 49.14 (-0.32), AMID: 10.97 (-1.05), ABBV: 66.94 (+0.71), FCCY: 12.40 (-0.10)
Global Biochip Market Worth USD 18.4 Billion by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: 3Qbd, Abaxis Inc, Emulate Inc - Research and Markets
BusinessWire - Thu May 05, 4:36AM CDT
Research and Markets has announced the addition of the "Global Biochip Markets: Microarrays and Lab-on-a-Chip" report to their offering.
ABAX: 49.14 (-0.32)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 24.43 (+0.15), CAPR: 3.58 (-0.12), CSII: 19.50 (-0.11), ABAX: 49.14 (-0.32)
Abaxis tops Street 4Q forecasts
Automated Insights - Thu Apr 28, 4:49PM CDT
UNION CITY, Calif. (AP) _ Abaxis Inc. (ABAX) on Thursday reported fiscal fourth-quarter earnings of $8.9 million.
ABAX: 49.14 (-0.32)
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2016 and Declares a 9% Increase in Quarterly Cash Dividend
PR Newswire - Thu Apr 28, 3:01PM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the fourth quarter and fiscal year ended March 31, 2016.
ABAX: 49.14 (-0.32)
Abaxis To Report Fourth Quarter And Fiscal Year 2016 Financial Results On Thursday, April 28, 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2016, ended March 31, 2016. The call will be at 4:15 p.m. ET on Thursday, April 28, 2016. The Company will report financial results for the fourth quarter and fiscal year 2016 after the market closes on Thursday, April 28, 2016.
ABAX: 49.14 (-0.32)
Global Veterinary Diagnostics Market Report 2014-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abaxis, HESKA, IDEXX Labs - Research and Markets
BusinessWire - Tue Apr 12, 7:26AM CDT
Research and Markets has announced the addition of the "Veterinary Diagnostics Global Market Analysis - Forecast (2014-2022)" report to their offering.
ABAX: 49.14 (-0.32)
Global Blood Gas and Electrolyte Analyzer Industry
PR Newswire - Mon Apr 04, 6:43PM CDT
This report analyzes the worldwide markets for Blood Gas and Electrolyte Analyzers in Units and US$ Thousand by the following Product Segments: Blood Gas Analyzers (Benchtop Analyzers, & Point-of-Care Analyzers), and Electrolyte Analyzers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -
ABAX: 49.14 (-0.32)
Abaxis Down 21.1% Since SmarTrend Downtrend Call (ABAX)
Comtex SmarTrend(R) - Mon Feb 08, 4:31PM CST
SmarTrend identified a Downtrend for Abaxis (NASDAQ:ABAX) on January 11th, 2016 at $51.04. In approximately 4 weeks, Abaxis has returned 21.14% as of today's recent price of $40.25.
ABAX: 49.14 (-0.32)
